Abstract: A lactic bacteria strain that is exogenous to the oral microflora is selected for its ability to adhere the pellicle of the teeth and to produce a growth inhibition factor. This strain is used for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries and other diseases related to Actinomyces naeslundii in mammals.

Abstract: Compositions for the prophylaxis or treatment of dental caries, dental plaque, and periodontal infection that include lactic bacteria that are not part of the resident microflora of the mouth, that are low acidifying, and that are capable of adhering directly to the pellicle of the teeth. The compositions are used in methods of treating or preventing dental caries, dental plaque, and periodontal infection.

Abstract: The present invention provides compositions for the prophylaxis or treatment of dental caries, dental plaque, and periodontal infection that include lactic bacteria that are not part of the resident micriflora of the mouth, that are low acidifying, and that are capable of adhering directly to the pellicle of the teeth. Preferably, the lactic bacteria of the include one or more of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, or Lactococcus lactis subsp. lactis biovar diacetylactis. The compositions are used in methods of treating or preventing dental caries, dental plaque, and periodontal infection.

Abstract: Compositions for the prophylaxis or treatment of dental caries, dental plaque, and periodontal infection that include lactic bacteria that are not part of the resident microflora of the mouth, that are low acidifying, and that are capable of adhering directly to the pellicle of the teeth. The compositions are used in methods of treating or preventing dental caries, dental plaque, and periodontal infection.

Abstract: A method for producing a beta-glucan from a non-pathogenic saprophytic filamentous fuingus or composition that contains it. Also, methods for providing this beta-glucan in a food product to improve structure, texture, stability or combinations thereof, in a food product to provide nutrition or in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumor or microbial infection.

Abstract: A lactic bacteria strain that is exogenous to the oral microflora is selected for its ability to adhere the pellicle of the teeth and to produce a growth inhibition factor. This strain is used for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries and other diseases related to Actinomyces naeslundii in mammals.

Abstract: A lactic acid bacterium having a 16S ribosomal RNA characteristic of the genus Streptococcus, cocci morphology, a growth optimum in the range of about 28° C. to about 45° C., having the ability to ferment D-galactose, D-glucose, D-fructose, D-mannose, and N-acetyl (D)-glucosamine, salicin, cellobiose, maltose, lactose, sucrose and raffinose, and imparting a viscosity of greater than 100 mPa.s at a shear rate of about 293 s−1. The strain often produces an exopolysaccharide comprising a chain of glucose, galactose and N-acetylglucosamine in a proportion of 3:2:1 respectively. The new strain is identified as Streptococcus macedonicus. Other characteristics include a total protein profile obtained after culture in an MRS medium for 24 h at 28° C., extraction of the total proteins and migration of the proteins on an SDS-PAGE electrophoresis gel, exhibits a degree of Pearson correlation of at least 78 with respect to bacterium CNCM I-1920 or I-1926.

Abstract: The present invention relates to a novel non-cellulosic bacterial extracellular polysaccharide, produced from the Gluconacetobacter spp. strain, and methods of using the polysaccharide and strain in the preparation of various foods.

Abstract: A method for producing a beta-glucan from a non-pathogenic saprophytic filamentous fungus or composition that contains it. Also, methods for providing this beta-glucan in a food product to improve structure, texture, stability or combinations thereof, in a food product to provide nutrition or in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumor or microbial infection.

Abstract: A lactic bacteria strain that is exogenous to the oral microflora is selected for its ability to adhere the pellicle of the teeth and to produce a growth inhibition factor. This strain is used for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries and other diseases related to Actinomyces naeslundii in mammals.

Abstract: Strain of lactic acid bacterium, (1) whose 16S ribosomal RNA is characteristic of the genus Streptococcus, (2) whose total protein profile, obtained after migration of the total proteins on an SDS-PAGE electrophoresis gel, is characteristic of that of the strain of lactic acid bacterium CNCM I-1920 but distinct from those of the recognized species belonging to the genus Streptococcus, namely S. acidominimus, S. agalactiae, S. alactolyticus, S. anginosus, S. bovis, S. canis, S. caprinus, S. constellatus, S. cricetus, S. cristatus, S. difficile, S. downei, S. dysgalactiae ssp. dysgalactiae, S. dysgalactiae ssp. equisimilis, S. equi, S. equi ssp. equi, S. equi ssp. zooepidemicus, S. equinus, S. ferus, S. gallolyticus, S. gordonii, S. hyointestinalis, S. hyovaginalis, S. iniae, S. intermedius, S. intestinalis, S. macacae, S. mitis, S. mutans, S. oralis, S. parasanguinis, S. parauberis, S. phocae, S. pleomorphus, S. pneumoniae, S. porcinus, S. pyogenes, S. ratti, S. salivarius, S. sanguinis, S. shiloi, S.

Abstract: A method for producing a beta-glucan from a non-pathogenic saprophytic filamentous fungus or composition that contains it. Also, methods for providing this beta-glucan in a food product to improve structure, texture, stability or combinations thereof, in a food product to provide nutrition or in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumor or microbial infection.

Abstract: Compositions for the prophylaxis or treatment of dental caries, dental plaque, and periodontal infection that include lactic bacteria that are not part of the resident microflora of the mouth, that are low acidifying, and that are capable of adhering directly to the pellicle of the teeth. The compositions are used in methods of treating or preventing dental caries, dental plaque, and infection.

Abstract: DNA fragment of genomic origin coding for at least one enzyme involved in the biosynthesis of an EPS, and capable, following the transformation of a lactic bacteria, of restoring the production of an EPS in the said bacterium not initially producing any EPS, or of modifying the structure of the EPS initially produced by the said bacterium. Proteins of the Streptococcus thermophilus strain CNCM I-1590 encoded by the chromosome and which are involved in the biosynthesis of the EPS having the composition Glc:Gal:GalNac=1:2:1. Method for the manufacture of a new EPS, in which a DNA fragment coding partially or totally for at least one enzyme involved in the biosynthesis of an EPS is cloned into a vector, lactic bacteria producing another EPS are transformed with the recombinant vector, and a lactic bacterium producing a new EPS is then selected.

Abstract: DNA fragment of genomic origin coding for at least one enzyme involved in the biosynthesis of an EPS, and capable, following the transformation of a lactic bacteria, of restoring the production of an EPS in the said bacterium not initially producing any EPS, or of modifying the structure of the EPS initially produced by the said bacterium. Proteins of the Streptococcus thermophilus strain CNCM I-1590 encoded by the chromosome and which are involved in the biosynthesis of the EPS having the composition Glc:Gal:GalNac=1:2:1. Method for the manufacture of a new EPS, in which a DNA fragment coding partially or totally for at least one enzyme involved in the biosynthesis of an EPS is cloned into a vector, lactic bacteria producing another EPS are transformed with the recombinant vector, and a lactic bacterium producing a new EPS is then selected.